

SUBJECT INDEX

- Adenocarcinoma**
 murine mammary, immunologic responses, 286
 x-ray-induced, blocking factors of, 335
- Albumin, serum, cellular basis of tolerance to, 497**
- Alloantigen**
 -induced T helper activity, 1897
 Ly-1, partial molecular characterization of, 53
 on B cells and Langerhans cells, immunofluorescent detection, 661
 subcellular dissociated and reconstituted, 1092
- Allotypes**
 α -chain, sequences of, 950
 immunoglobulin heavy chain, 812
 light chain, 624
- Anaphylotoxins, C3a and C5a, human, chemotactic response to, 109**
- Angioedema, assay of plasminogen in, 592**
- Anisakis and eosinophil chemotaxis, 745**
- Antibody**
 absence of ability to secrete, generation of low dose paralysis in, 986
 against receptor for IgE, 507
 anti-dextran, comparison with protein 104E, 1143
 anti-idiotypic, homologous and isologous, 233
 C killing, lipids and resistance to, 472
 -complement stimulation of lipid synthesis, 895
 erythrocyte autoantibody responses, 825
 Fc portion, in antigen-antibody complex-mediated suppression, 1669
 human natural, FCS protein reactive with, 646
 idiotypic, isolation of, 293
 IgE
 and IgG, comparison of binding of, to honeybee venom phospholipase-A, 1917
 quantitative measurements of, 1201
 regulation of production by serum molecules, 2050, 2060
 IgG1, cutaneous basophil hypersensitivity mediated by, 886
 immunosuppressive, against endogenous C-type virus, 1913
 -induced suppression of murine C5, 400
 levels, regulation of, 1063
 lipid metabolism stimulated by, 1644
 responses
 in trypanosomiasis, 759
 to DNP-GLO, 46
 transient IgE, 837
 -sensitized target cells, lysis by murine T cells, 244
 suppression of tumor growth by, 831
 to *Aspergillus fumigatus* antigens, 66
 to single stranded RNA in systemic lupus erythematosus, 550
- Anti-fructofuranans, recombinant, binding studies on, 408**
- Antigen**
 -antibody complex-mediated suppression, requirement for Fc in, 1669
 antigenic modulation *in vitro*, 188
 antigenic reactivity, C3NeF polypeptide chains and, 1389
 Aspergillus fumigatus, antibody to, 66
 B16 melanoma, partially purified, immunization to, 96
 -binding cells, purification of, 1233
 capsular polysaccharide, of *Haemophilus influenzae* type B, 866
 cell surface on macrophages, relation to tumor cell cytotoxicity, 2080
 feeding
 effects on immune responses, 1509
 T cell priming by, 395
 follicular, and regulation of antibody levels, 1063
 H-2 transplantation, third, 1836
 hepatitis B surface, thermal inactivation, 40
- Ia**
 embryologic expression, 818
 murine, 1659
 on Langerhans cells, 570
 on plasma cells, 1480
 subunits, 671
 inhibition of cytolytic T lymphocyte activity by, 1544
 -initiated B lymphocyte differentiation, 911
 lipid-conjugated, 734
 macrophage Ia, 378
 major histocompatibility complex, chemical characterization, 607
 oncornavirus-directed tumor cell surface, 1663
 polypeptide, of HBs Ag, 520
 recognition, T lymphocyte, adherent cell function in, 1991
 -responsive clones, inactivation of, 1139
 Salmonella O, 1750
 -specific augmenting T cell factor, 414
 surface, on Epstein-Barr virus-carrying cells, 1702
 T lymphocyte, isolation of, 1429
 Thy-1, shed, characteristics, 1651
 tumor, of methylcholanthrene-induced sarcoma, 1981
- Antiserum**
 inhibition of cytolytic T lymphocyte induction, 1717
 syngeneic, to L₂C leukemia, 597
 to mouse cytotoxic T lymphocytes and their precursors, 209
- Anti-Thy 1.2, effects on bone marrow in irradiated mice, 754**
- Arthritis, adjuvant, T cell subpopulations in, 1127**
- Aspergillus fumigatus* antigens, antibody to, 66**
- Autoantibody, natural thymocytotoxic, differential cytotoxic effect of, 1924**
- Azobenzeneearsonate, tolerance to, 202**
- Bacillus Calmette Guérin-induced suppressor cells, 563**
- Bacterial adherence to mouse lymphocyte subsets, 167**
- Bacteroids melaninogenicus*, lipopolysaccharide of, 72**
- Basophil hypersensitivity, colonic, 198**
- C57BL/10/CR mice, nonresponders to lipid A, 249**
- Candida albicans*, protection against, by transferred immune serum, 1176**
- Carrageenan, effects on immune responses, 61**
- Cell, *see also* specific types of cell**
 ADCC effector, intra-tumor localization of, 1813
 adherent
 action of normal mouse serum on, 1550
 function in murine T lymphocyte antigen recognition, 1991
 allogeneic, of human lymphocyte subpopulations and mitogens separated by differential binding to monolayers of bacteria, 2020
 alveolar, C4-producing, 716
 antigen-binding, purification of, 1233
 autochthonous, allogeneic, and xenogeneic as targets for vaccinia immune lymphocyte cytotoxicity, 312
- B**
 activation, molecular basis of, 694
 activation of suppressor T cells in melanoma, 1573
 alloantigens on, immunofluorescent detection of, 661
 colony-forming, 1289
 CR⁺ and CR⁻, activation of, 750
 differentiation induced by lipopolysaccharide, 158
 hapten-specific blockade, 1362
 hapten-specific, fractionation of, 145
 polyclonal, suppression of, in scrapie-infected mice, 1986
 responses, macrophage products and, 1818
 role of monocytes in *in vitro* response of, 1283
 cellular basis of idiotype-specific suppression, 2016
 cellular receptors for lymphokines, 542
 cytotoxic, for syngeneic tumor cells in mice, 1218
 Epstein-Barr, virus-carrying, surface antigen on, 1702
 immunoglobulin-secreting, 33
 impairment of cellular immunity in db/db mice, 1375

Cell, B—*continued*

K

- E-rosette formation by, 90
- thymus-processed, 244
- kinetics, of response to phytohemagglutinin, 955
- L, Ca⁺⁺ uptake by, 279
- Langerhans
 - alloantigens on, immunofluorescent detection of, 661
 - Ia antigens on, 570
- Lyb-3, molecular identification of, 1733
- lymphoblastoid, release of Thy-1.2 and Thy-1.1 from, 1651
- lymphoid
 - effects of passive transfer on murine candidiasis, 1176
 - incompatible, rejection by nude mice, 79
 - in situ*, of mouse mammary tumors, 1876, 1881, 1887
- lymphoma, inhibition in irradiated mice, 1679
- mast cell-derived eosinophil chemotactic factors, 15
- mediated cytotoxicity
 - IgM- and IgG-dependent, 1726
 - spontaneous, 1849
- mediated hypersensitivity in viral myocarditis, 1672
- mediated immune response, 1604
- mediated immunity dependent on lymphokine-mediated collaboration between T lymphocytes, 1957
- mediated lympholysis of trinitrophenyl-derivatized autologous cells, 630
- membranes, lymphoid, alteration of, 1631
- mononuclear
 - production of slow reacting substance of anaphylaxis by, 998
 - surface receptors on, 1014
- permeabilized, nucleotide triphosphate incorporation by, 1930
- plaque-forming, response, suppression by macrophages, 357
- plasma
 - Ia-antigens on, 1480
 - suppression of maturation, 158
- populations, immunosuppressive, evolution of, 1709
- pre-B, in anti- μ -suppressed mice, 1526
- specific killer, *in vitro* production of, 286
- spleen
 - concanavalin A-activated, soluble immune response suppressor produced by, 481
 - stimulation, herpes simplex virus induced, 641
- suppressor
 - activity in tumor-bearing mice, 1345, 1354
 - and cytotoxic, activation by Con A, 1828
 - BCG-induced, 563
 - function, mechanisms, 700
 - histamine binding, 1268
 - in spleens of mice bearing methycho-lanthrene-induced tumors, 2033
 - surface antigen on macrophages, relation to tumor cell cytotoxicity, 2080
 - surface immunoglobulin, 353

T

- activating factors, induction in J774.1, 1097
- carrier-specific helper, enhancement of, 980
- cytotoxic, clones of, 340
- F₁ subpopulations, 638
- factor, antigen specific augmenting, 414
- growth factor, 2027
- helper and amplifier, 579
- helper, generation of, 445
- helper, in JgG3 response, 1195
- human suppressor, 902
- membrane components bound to β_2 -microglobulin, 513
- memory in antibody responses, 1021, 1028
- priming by antigen feeding, 395
- response to staphylococcal nuclease, 1741
- subpopulations, in delayed hypersensitivity, 137
- subpopulations, imbalances in multiple sclerosis patients, 1369
- subpopulations, in adjuvant arthritis, 1127
- subsets, functional, 1423
- suppressor and helper, 497
- suppressor, for IgE and IgG in Peyer's patches, 861
- suppressor, role in IgE antibody response, 837
- target conjugates, inhibition of, 774
- with regulatory functions, 1278
- thymic epithelial
 - effects of vitamin B6 deficiency on, 1153
 - of New Zealand mice, 971
 - tolerance in the chicken, 1046
- tumor
 - sensitivity to killing and lipid synthesis in, 463
 - stimulation of lipid synthesis in, 895
- Chemotactic factors, competitive antagonism of, 1326
- Chimeras, germfree, partial immunocompetence in, 1274
- Cholera, toxin and modulation of hemolysin formation, 452
- Clones
 - antigen-responsive, inactivation of, 1139
 - cytotoxic, specificity and cross-reactivity, 425
- Complement
 - alternative pathway,
 - activation by pneumococcal cell wall teichoic acid, 174
 - modulation of, in serum, 1404
 - antibody-complement stimulation of lipid synthesis, 895
- C1, binding and activation of, by the lipid A region of lipopolysaccharides, 1862
- C1q-dependent cell lysis, 27
- C3
 - activated phagocytosis by lung macrophages, 1305
 - cutaneous, in graft-*vs*-host disease, 1485
 - mediated phagocytosis, trypan blue and, 1580
 - receptors, 879
 - requirement in modulation of thymus-leukemia antigenicity, 188
- C4
 - deficiency, chemotaxis and opsonization in, 1102
 - producing alveolar cells, 716
 - C5, antibody-induced suppression of, 400
 - C5b and C6, complex of, 1841, 2008
 - C6 deficiency, 538
 - dependent stimulation of normal lymphocytes by immune complexes, 806
 - depletion in cryptococcal sepsis, 1686
 - induced modifications in membrane fluidity, 2003
 - inhibition by gold sodium thiomalate, 1625
 - interacting factors of *Taenia taeniaeformis*, 1039
 - leukocyte, 850, 855
 - lipid metabolism stimulated by, 1644
 - membrane damage by, 1996
 - role in zymosan-platelet interaction, 9
 - system, classical, of mice, 216
 - Taenia taeniaeformis* and, 1033
- Complex, immune, complement-dependent stimulation of normal lymphocytes by, 806
- Concanavalin A
 - activation of human suppressor and cytotoxic cells by, 1828
 - cytotoxic T lymphocyte induction by, 1086
 - transfer, in cell-mediated mitogenic response, 788
- Contamination, endotoxin, of biologic preparations, 1760
- Costimulator
 - effects on immune response, 1974
 - for mitogenic response of thymocytes, 1967
- Coxsackievirus B3, viral-induced myocarditis, 1672
- ⁵¹Cr release data, interpretation of, 991
- α -Crystallin determinants, distribution and immunogenicity, 586
- Cytotoxicity
 - cell-mediated, role of interferon and immunoglobulins, 1849
 - lymphocyte-mediated, 312
 - macrophage-mediated, 347
 - natural, suppression of, 239
- Daudi cell membrane fractions, detection of cell surface antigens against, 1587
- Digitalis, mitogenicity of, 694
- Disease, *see also* specific types of disease
 - virus-induced immune complex disease, 1297
- DNA synthesis and polymerases, inhibition of, 1345
- Encephalomyelitis, experimental allergic, suppression of, by EN3638, 602
- Endotoxin
 - contamination, of biologic preparations, 1760
 - resistance, inflammatory response and, 116
- Enterotoxins, staphylococcal, cross-reactions in, 86
- Erythrocyte
 - autoantibody responses, 825
 - modified syngeneic, 844
- Erythroleukemia, regression of, 1

- Factor
 B, fragments, biologic activities of, 438
 eosinophil chemotactic, in peritoneal mast cells, 15
 lipid chemotactic, immunologic release of, 102
 suppressive, from tolerant mice, 21
- Fc receptor
 lymphocytes, 1869
 subclass specificity of, 1395
- γ -Globulin
 -induced tolerance, 1824
 tolerance induction to, 1046
- Gene
 Cy, latent expression of, 1160
 Ir,
 complementation in response to phage fd, 2087
 control, major histocompatibility complex-linked, 1741
 I region-specific, 1809
 Ir-Z, control of unresponsiveness by, 1460
- Glycoprotein, H-2D mutant, 726
- Graft-*vs*-host disease
 cutaneous IgM and C3 in, 1485
 suppression, 1340
- Granulocyte binding, structural requirements of human IgG for, 1952
- H-2 genes influencing Friend virus leukemia, 1081
- Haemophilus influenzae* type B, ^3H -labeled capsular polysaccharide of, 866
- Hapten
 -coated liposomes, suppression of reagins with, 1612
 -specific
 B cell blockade, 1362
 B lymphocytes, 145
 tolerance, 1824
- Hemolysin formation, cholera toxin-mediated modulation of, 452
- Hemolysis, terminal stages of, 1721
- Hepatitis B surface antigen
 polypeptide antigens of, 520
 thermal inactivation, 40
- Hepatitis virus, type 3, mouse, role of interferon, 1616
- Hepatocarcinoma, line 10, suppression of growth, 831
- Herpes simplex virus-induced spleen cell stimulation, 641
- Histamine
 -binding suppressor cells *in vitro*, 1268
 release, by anti-IgE receptors, 800
- Histocompatibility complex, major, phenotypes of, 179
- 12-L-Hydroxy-5,8,10-heptadecatrienoic acid, PMN leukocyte chemotactic activity of, 526
- Hypersensitivity
 colonic basophil, 198
 delayed, T cell subpopulations in, 137
 delayed-type, suppression of, 1509
- Immune response, *see* Response, immune
- Immunity, cellular, to solubilized tumor antigens of methylcholanthrene-induced sarcoma, 1981
- Immunocompetence, partial, in germfree chimeras, 1274
- Immunodeficient patients, natural killing in, 796
- Immunodepression, reticuloendotheliosis virus-induced, 1321
- Immunogenicity, liposomal composition and, 1109
- Immunoglobulin
 allotypes, chicken, 75, 812
 anti-Ig modulation of spleen cell Ig secretion, 1465
 anti-IgG receptors, histamine release by, 800
 anti-immunoglobulin stimulation of murine lymphocytes, 1907
 -bearing human peripheral blood lymphocytes, 124
 binding of, to staphylococcal protein A, 1493
 cell surface, 353
 comparison of binding of IgE and IgG antibodies to honeybee venom phospholipase-A, 1917
 conventional, on thymocytes from primitive vertebrates, 2068, 2074
 derived from myeloma anti-fructofuranans, 408
 domains, structure and function, 1952
 dual specificities of, 411
 Fc portion, lymphocytes expressing receptors for, 1869
- Ig A
 deficiency, selective, 932
 milk, binding to jejunal epithelium in suckling rats, 1333
- IgD, appearance on murine lymphocytes during differentiation, 353
- IgE
 and IgG in Peyer's patches, suppressor T cells for, 861
 antibodies against receptor for, 507
 antibodies, quantitative measurements of, 1201
 antibody production, regulation by serum molecules, 2050, 2060
 -bearing lymphocytes, ontogeny of, 655
 extravascular catabolic pathway for, 1696
 isolation of the receptor for, 429
 suppression and Ig-1 allotype in SJL mice, 1758
- IgG
 aggregated, binding to lipopolysaccharides, 317
 and complement roles in zymosan-platelet interaction, 9
 -IgM ratios, 1021
 immunoregulatory function of, 652
 protein-protein interactions of, 739
 structural requirements of, for granulocyte binding, 1952
- IgG1 antibodies, cutaneous basophil hypersensitivity mediated by, 886
- IgG3 response, helper T cells in, 1195
- IgM
 antibodies, lipopolysaccharide induction of, to polyadenylic acid, 1856
 cutaneous, in graft-*vs*-host disease, 1485
 production in the chick, regulation of, 783
- kappa light chain gene, linkage to, 1832
- role in spontaneous cell-mediated cytotoxicity, 1849
 -secreting cells, 33
 sequential expression of, on developing mouse B lymphocytes, 2041
- Immunosuppression, by ascites fluid from mastocytoma-bearing mice, 558
- Influenza, 1447
 virus, monoclonal immune response to, 1164
- Interferon
 role in pathogenesis of viral diseases, 1616
 role in spontaneous cell-mediated cytotoxicity, 1849
- Intramembrane particle distribution, alterations in, 151
- Killing, natural, in humans, 796
- Langerhans cells
 alloantigens on, immunofluorescent detection of, 661
 Ia antigens on, 570
- Leukemia
 Friend virus, H-2 genes influencing, 1081
 hairy cell, 777
 L₂C
 syngeneic antisera to, 597
 tumor-associated transplantation antigen of, 1521
- Leukocyte
 -adherence inhibition, 0000
 basophilic, plasminogen activator of, 766
 complement, 850, 855
 human, herpesvirus replication in, 130
 inhibitory factor, 1409
 membrane receptors of, 879
 polymorphonuclear
 complement-mediated phagocytosis by, 1580
 glutathione-deficient, microtubules in, 1181
 leukocyte chemotactic activity of HHT, 526
- Levan, immune response to, 1436
- Lipid
 -altered tumor membranes, 1637
 and resistance to antibody C killing, 472
 -conjugated antigen, 734
 metabolism stimulated by antibody and complement, 1644
 synthesis in tumor cells, 463
- Lipopolysaccharide
 B cell differentiation induced by, 158
 induction of IgM antibodies to polyadenylic acid, 1856
 lipid A region of, binding and activation of C1 by, 1862
 of *Bacteroides melaninogenicus*, 72
 response gene, linkage of, 422
- Liposomal composition, and immunogenicity, 1109
- Liposomes, hapten-coated, suppression of reagins with, 1612
- Lymphocytes
 activated
 measurement of DNA synthetic capacity of, 1930
 separation of nylon wool columns of, 1028
 -activating factor produced by the macrophage cell line, P388D, 1497, 1504

Lymphocytes—*continued*

- activation, acceleration of, by culture, 532
- allosensitized, inhibition of tumor growth by, 619
- antibody-dependent cell-mediated cytotoxicity by, 1726
- antigens, T and B, 262
- B**
 - BCG activation of, 254
 - differentiation, antigen-initiated, 911
 - human, activation of, 700
 - human, responsiveness, 902
 - precursors in human bone marrow, 1169
 - sequential expression of immunoglobulin on, 2041
- circulation, lactic dehydrogenase virus alteration of, 459
- cytolytic T, 1121
 - induction, 1114, 1717
- cytotoxic activity of, 385
- cytotoxic, cross-reactivity of, 425
- cytotoxic proteinase isolated from, 665
- cytotoxic T
 - and their precursors, antiserum to, 209
 - induction by concanavalin A, 1086
- DNA synthesis and proliferation of, 955, 963
- electrophoretic mobilities, 921
- Fc receptor, 1869
- function in experimental African trypanosomiasis, 759
- human peripheral blood, immunoglobulin-bearing, 124
- IgE-bearing, ontogeny of, 655
- induced immune deviation, 689
- interaction with radiolabeled 2-ME, 1453
- macrophage-mediated sensitization of, 1947
- mediated cytotoxicity, 312
- mixed lymphocyte culture, cytotoxicity generated in, 1415
- murine, anti-immunoglobulin stimulation of, 1907
- normal, complement-dependent stimulation of, by immune complexes, 806
- proliferation, mitogen induced, effect of D-penicillamine on, 1006
- subpopulations
 - detected by anti-Daudi sera, 1587
 - glycolipid markers of, 676
 - identification by natural binding of bacteria, 167
- T**
 - antigen, isolation of, 1429
 - antigen recognition, 1991
 - cell-mediated immunity dependent on lymphokine-mediated collaboration between, 1957
 - cytolytic, induction by secondary MLC supernatants, 370
 - cytotoxic, cell lysis by, 1261
 - helper and suppressor, separation of, 1149
 - peripheral, thymopoietin and, 1594
 - self reactivity, increase in aging inbred rats, 1249
 - specific binding of, to macrophages, 1902
 - specificity, and activity of I region specific Ir genes in macrophages and B lymphocytes, 1809

- suppression by, 1345
- target cell interaction, 1378
- teratoma-sensitized, anti-tumor activity of, 1211
- Lymphokine**
 - activated peritoneal exudate macrophages, 1054
 - cellular receptors for, 542
 - for mitogenic response of thymocytes, 1967
- Lymphoma**
 - cells, inhibition in irradiated mice, 1679
 - virus-induced, suppression by, 1473
- Lymphotoxin**
 - action of, antagonists, 272 Ca⁺⁺ uptake by L cells, 279
- α -Lymphotoxin, cellular origin, 385
- Macrophage**
 - activation
 - in hypersensitivity pneumonitis, 685
 - markers of, 1533
 - C3H/HeJ, tumoricidal defect of, 329
 - Fc_γ-binding protein, 709
 - Ia antigens, 378
 - lung, C3-activated phagocytosis by, 1305
 - mediated cytotoxicity, 347
 - mediated *in vitro* sensitization of lymphocytes, 1947
 - peritoneal exudate, lymphokine-activated, 1054
 - PGE₁ sensitivity and PGE₁ production of, 1187
 - products, and B cell responses, 1818
 - regulatory role in immune responses of low responder mice, 61
 - role in regression of erythroleukemia, 1
 - specific binding of T lymphocytes to, 1902
 - suppression by, 1345
 - suppression of the plaque-forming cell response by, 357
 - suppressor, in Marek's disease virus spleens, 1554
 - tumor cell line J774.1, induction of T cell activating factor(s) in, 1097
 - tumor suppression by, 1560
- Marek's disease virus spleens, suppressor macrophages in, 1554
- Mastocytoma-bearing mice, immunosuppression by ascites fluid from, 558
- Melanoma**
 - antigens, partially purified, immunization to, 96
 - B cell activation of suppressor T cells in, 1573
- Methylcholanthrene**
 - induced sarcoma, cellular immunity to tumor antigens of, 1981
 - induced tumors, suppressor cells in spleens of mice bearing, 2033
- β_2 -Microglobulin, T cell membrane components bound to, 513
- Migration inhibition factor, production by T cell subsets, 927
- Mitogens, and allogeneic cells of human lymphocyte subpopulations separated by differential binding to monolayers of bacteria, 2020
- Monocytes**
 - human, purification of, 1372
 - locomotion, cyclic nucleotide control of,

- 492
- role in *in vitro* response of human B cells, 1283
- Monosaccharides, inhibition of chemotactic factors with monosaccharides, 542
- MOPC-315, idiotype-specific transplantation resistance to, 1620
- Muramyl dipeptide
 - adjuvant action of, 487
 - adjuvant effect of, 980
- Myeloma**
 - proteins, subclass specificity for binding of, 1395
 - specific resistance, CFA stimulation to, 613
- Myocarditis, viral, cell-mediated hypersensitivity in, 1672
- Myoglobin, H-2-linked Ir genes for, 360
- Neutrophils, in tumor rejection, 1240
- Oncornavirus-directed tumor cell surface antigens, 1663
- Opsonic activity, reduction of, 983
- Opsonin-independent phagocytosis by monocytes, 1132
- Orchitis, allergic in the rabbit, 320
- Parainfluenza type I virus, immune response to, 1256
- Paralysis, low dose, generation of, 986
- D-Penicillamine inhibition of mitogen responsiveness, 1006
- Peyer's patches, role in immune response of rabbit ileum to live bacteria, 1892
- Phage fd, Ir gene complementation in response to phage fd, 2087
- Phagocytosis**
 - C3-activated, by lung macrophages, 1305
 - complement-mediated, 1580
 - opsonin-independent, by monocytes, 1132
- Phytohemagglutinin-stimulated lymphocyte proliferation, kinetics of, 955, 963
- Plasma cell maturation, suppression of, 158
- Plasminogen**
 - activator
 - inducer of, production by T cell subsets, 927
 - of basophilic leukocytes, 766
 - functional and immunologic assay of, 592
- Pneumonitis, hypersensitivity, macrophage activation in, 685
- Polypeptide chains, C3NeF, and antigenic reactivity, 1389
- Polysaccharide, ³H-labeled capsular, of *Haemophilus influenzae* type B, 866
- Protein**
 - 104E, anti-dextran antibody compared with, 1143
 - A, mitogenic activity of, 302
 - fetal calf serum, reactive with human natural antibodies, 646
 - macrophage Fc_γ-binding, 709
 - murine S, 225
 - myeloma, subclass specificity for binding of, 1395
 - protein interactions of IgG, 739
 - senile cardiac amyloid fibroid, 1385
- Proteinase, human lymphocyte cytotoxic, 665

- Reactivity, autoimmune, age-dependent, 1249
- Reagins, suppressions of, 1612
- Rejection, skin graft, allogeneic, 1600
- Release, mediator, potentiation by adenosine, 871
- Response, *see also* specific type of response
 antibody, T cell memory in, 1021, 1028
 anti-hapten antibody, splenic T cells regulating, 579
 chemotactic to human C3a and C5a anaphylotoxins, 109
 cytotoxic, elicited by alloantigens determined by second D region locus, 1836
 erythrocyte autoantibody, 825
 idiotype, cross-reactive, 1436
 immune
 aging and, 939, 944
 altered, and *T. pallidum*, 1691
 cell-mediated, regulation of, 1604
 CNS-associated, 1256
 during human *Schistosomiasis mansoni*, 1225
 effects of carrageenan on, 61
 effects of costimulator on, 1974
 intestinal and systemic, effects of antigen-feeding on, 395, 1509
 monoclonal, to influenza virus, 1164
 of rabbit ileum to live bacteria, 1892
 pharmacologic control, 1600
 stimulation by muramyl dipeptide, 487
 suppression by factor from tolerant mice, 21
 to immunization via the anterior chamber of the eye, 689
 to levan, 1436
 to myoglobins, 360
 to phosphorylcholine, 233
 inflammatory, and endotoxin resistance, 116
 mitogenic, cell-mediated, concanavalin A transfer in, 788
 plaque-forming cell, suppression by macrophages, 357
- Reticuloendotheliosis virus
 -induced immunodepression, 1321
 -induced tumorigenesis, suppression during, 1313
- Runt disease, prevention, 1600
- Salmonella O-antigens, 1750
- Sarcoma, methylcholanthrene-induced, cellular immunity to tumor antigens of, 1981
- Schistosoma mansoni*, nonspecific resistance to, genetic control of, 1070
- Schistosomiasis, suppressor cells in, 1074
- Schistosomiasis mansoni*, immune responses during, 1225
- Sclerosis, multiple, imbalances in T cell subpopulations in, 1369
- Scrapie-infected mice, suppression of polyclonal B cell activation in, 1986
- Sensitivity, contact, to DNFB, tolerance and, 137
- Serum
 albumin, cellular basis of tolerance to, 497
 alternative pathway in modulation of, 1404
 anti-Daudi, human lymphocyte subpopulations detected by, 1587
 anti-interferon, 1616
 molecules, regulation of IgE antibody production by, 2050, 2060
 mouse, normal, action on adherent cells, 1550
 protein, gene, linkage to Kappa light-chain gene, 1832
- Soluble immune response suppressor (SIRS), mode of action of, 481
- Staphylococcal enterotoxins, cross-reactions in, 86
- Staphylococcal protein A, binding of murine immunoglobulins to, 1493
- Staphylococcus aureus*, protein A from, 302
- Subclass specificity, of Fc receptors, 1395
- Suppression
 during REV-induced tumorigenesis, 1313
 idiotype-specific, cellular basis of, 2016
- Suppressor
 factor, tumor-specific, 1218
 soluble immune response (SIRS), mode of action, 481
- Systemic lupus erythematosus, antibodies to single stranded RNA in, 550
- T helper activity, alloantigen-induced, 1897
- Taenia taeniaeformis*, and complement, 1033
- Teichoic acid activation, of alternative pathway, 174
- Teratoma-sensitized lymphocytes, anti-tumor activity of, 1211
- Thymectomy, role in reversal of myeloma immunity, 1620
- Thymocytes
 control and cortisone-resistant, 244
 from primitive vertebrates, conventional immunoglobulin on, 2068, 2074
 lymphokine required for mitogenic response of, 1967
- Thymopoietin, and peripheral T lymphocytes, 1594
- Thymus-processed K cells, 244
- Tolerance
 and contact sensitivity to DNFB, 137
 D-GL and isologous γ -globulin-induced, 1824
 induced by modified syngeneic erythrocytes, 844
 T cell in the chicken, 1046
 to azobenzenearsonate, 202
- Toxoplasma gondii*-infected mice, 939
- antibody formation and chronic infection in, 939
- lymphocyte responsiveness and macrophage activation in, 944
- Treponema pallidum*, altered immune responses and, 1691
- Trypanosomiasis, antibody responses in, 759
- Tumor, *see also* specific types of tumor
 antigens, of methylcholanthrene-induced sarcoma, 1981
 anti-tumor activity of teratoma-sensitized lymphocytes, 1211
 -associated transplantation antigen of L₂C leukemia, 1521
 -bearing host, suppressor cell activity in, 1345, 1354
- cells
 cytotoxicity, relation of expression of cell-surface antigen on macrophages to, 2080
 sensitivity to killing and lipid synthesis in, 463
 stimulation of lipid synthesis in, 895
 surface antigens, oncornavirus-directed, 1663
 syngeneic, cells cytotoxic for, 1218
 cytotoxicity, macrophage activation for, 1054
- growth
 inhibition by allosensitized lymphocytes, 619
 suppression *in vivo*, 1941
- intra-tumor localization of ADCC effector cells, 1813
- mammary, *in situ* lymphoid cells of, 1876, 1881, 1887
- membranes, lipid-altered, 1637
- methylcholanthrene-induced, suppressor cells in spleens of mice bearing, 2033
- rejection, neutrophils in, 1240
- specific suppressor factor, 1218
- suppression, by macrophages, 1560, 1567
- Tumorigenesis, reticuloendotheliosis virus-induced, suppression during, 1313
- Unresponsiveness, control by IR-Z genes, 1460
- Virus, *see also* specific type of virus
 C-type, endogenous, immunosuppressive activity against, 1913
 Friend virus-induced erythroleukemia, regression of, 1
 herpes simplex, replication in human leukocytes, 130
 -induced immune complex disease, 1297
 -induced lymphoma, suppression by, 1473
 lactic dehydrogenase virus alteration of lymphocyte circulation, 459
 Vitamin, B6, deficiency, and thymus function, 1153

METRIZAMIDE

Metrizamide is a non-ionic compound for density gradient centrifugation experiments. It is inert and forms solutions which, while much denser than can be obtained with sucrose, have relatively low viscosity and osmolarity.

Metrizamide is non-toxic to cells. Metrizamide has proved most useful in the fractionation of nucleic acids, nucleoproteins, most subcellular particles and organelles as well as cells and viruses (Rickwood, D. & Birnie, G.D.:FEBS letters,50, 2(1975)102).

Now available in two purification grades.

1 Metrizamide C Grade AN6400.

Centrifugation Grade with a lower price. The cost per gradient is similar to that of other high quality density gradient media.



2 Metrizamide A Grade AN6300.

Analytical Grade for experiments that require ultrapure material.



For further information contact:

ACCURATE CHEMICAL & SCIENTIFIC CORPORATION

28 Tec Street, Hicksville, N.Y. 11801/Tel: (516) 433-4900

Other countries, contact:

NYEGAARD & CO. A/S, Post Office Box 4220, Oslo 4, Norway

The North American
distributor for
NYEGAARD



Samples and scientific literature available

Name _____

Institution _____

Address _____

STANDARDIZED REAGENTS for MICROBIOLOGICAL and LABORATORY PROCEDURES

Dehydrated and Prepared Culture Media
Tissue Culture Media, Sera & Reagents

Sensitivity Disks
Carbohydrates
Stains Dyes
Antigens & Antisera
Dispens-O-Disc

F A Reagents
Peptones
Hydrolysates
Indicators
Clinical Reagents
Enrichments

Biochemicals
Amino Acids
Enzymes
Serological Reagents
Extracts

DIFCO PRODUCTS ARE USED ROUTINELY WHEREVER MICROBIOLOGICAL PROCEDURES ARE PERFORMED

Hospital Clinical Laboratory—Microbiology, Tissue Culture, Serology.
Public Health Laboratories—water, sewage, dairy and food products.
Quality control of pharmaceutical, chemical and industrial products.
Educational and Research programs in related sciences and technology.

Difco Laboratory Products and Reagents are available through local
laboratory supply dealers

DIFCO
LABORATORIES
DETROIT, MICHIGAN 48232 USA